DGCR.F Stock Overview
9342-8530 Québec Inc., a life sciences company, develops and commercializes products relating to the diagnosis of cancer in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
9342-8530 Québec Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -99.91% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| DGCR.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -5.0% | -3.5% |
| 1Y | n/a | -1.7% | 20.2% |
Return vs Industry: Insufficient data to determine how DGCR.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how DGCR.F performed against the US Market.
Price Volatility
| DGCR.F volatility | |
|---|---|
| DGCR.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DGCR.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DGCR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | Yves Fradet | www.diagnocure.com |
9342-8530 Québec Inc., a life sciences company, develops and commercializes products relating to the diagnosis of cancer in Canada. It focuses on molecular diagnostic tests for the detection and management of cancer. The company offers PCA3 test for the diagnosis of prostate cancer; and Guanylyl Cyclase C (GCC) marker and Previstage GCC colorectal cancer staging test for colorectal cancer patients, as well as PCP, a multi marker prostate cancer test.
9342-8530 Québec Inc. Fundamentals Summary
| DGCR.F fundamental statistics | |
|---|---|
| Market cap | US$43.00 |
| Earnings (TTM) | US$1.99m |
| Revenue (TTM) | US$4.86m |
0.0x
P/E Ratio0.0x
P/S RatioIs DGCR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DGCR.F income statement (TTM) | |
|---|---|
| Revenue | CA$6.68m |
| Cost of Revenue | -CA$139.13k |
| Gross Profit | CA$6.82m |
| Other Expenses | CA$4.08m |
| Earnings | CA$2.74m |
Last Reported Earnings
Jul 31, 2016
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did DGCR.F perform over the long term?
See historical performance and comparison